Business
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clin
About this update from Atyr Pharma, Inc.
[{"type":"image","alt":"aTyr Pharma, Inc.","displaySize":"","headline":null,"caption":"aTyr Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3m4LnsxUZVB.dx6N.MAnrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791","width":300,"height":179}},"lazy":false},{"type":"text","content":"Clinical benefit for efzofitimod across multiple disease-related health outcomes reported.","length":90,"tagName":"p"},{"type":"text","content":"Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226).","length":139,"tagName":"p"},{"type":"text","content":"Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197).","length":156,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in a late-breaking oral abstract presentation by Daniel Culver, D.O., Chair of the Department of Pulmonary Medicine at the Cleveland Clinic and principal investigator of the study, at the European Respiratory Society (ERS) Congress 2025 in Amsterdam, Netherlands.","length":695,"tagName":"p"},{"type":"text","content":"“Building on the positive data we presented in the topline results for the King’s Sarcoidosis Questionnaire (KSQ)-Lung score, the clinical improvements in the Fatigue Assessment Scale (FAS) and KSQ-General Health scores presented at ERS are compelling because these directly address critical symptoms and quality of life measures that profoundly impact pulmonary sarcoidosis patients,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “Crucially, the improvements observed for the KSQ-Lung, FAS and KS...